Barrington Research Maintains Outperform on Haemonetics, Maintains $108 Price Target
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has reiterated an 'Outperform' rating for Haemonetics (NYSE:HAE) and maintained a price target of $108.
September 23, 2024 | 2:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barrington Research has reaffirmed its 'Outperform' rating for Haemonetics, maintaining a price target of $108. This suggests confidence in the company's performance and potential for stock price appreciation.
The reaffirmation of the 'Outperform' rating and the maintenance of a $108 price target by Barrington Research indicates a positive outlook on Haemonetics' stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100